Atr Rehabil Med 5, 376 (2012). 7. Harmatz, P. et al. Long-term follow-up of endurance and security outcomes through enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab 94, 4695 (2008). 8. McDonald, A., Steiner, R., Kuehl, K. Turbeville, S. Clinical utility of endurance measures for evaluation of treatment in individuals with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr Rehabil Med three, 1197 (2010). 9. Sohn, Y. B. et al. Enzyme replacement therapy improves joint motion and outcome on the 12-min walk test within a mucopolysaccharidosis type VI patient previously treated with bone marrow transplantation. Am J Med Genet A 158A, 11583 (2012). ten. Auclair, D., Hopwood, J. J., Lemontt, J. F., Chen, L. Byers, S. Long-term intraarticular administration of recombinant human N-acetylgalactosamine-4sulfatase in feline mucopolysaccharidosis VI. Mol Genet Metab 91, 3521 (2007). 11. Cotugno, G. et al. Long-term amelioration of feline Mucopolysaccharidosis VI after AAV-mediated liver gene transfer. Mol Ther 19, 461 (2011). 12. Cotugno, G. et al. Diverse serum enzyme levels are needed to rescue the numerous systemic characteristics from the mucopolysaccharidoses. Hum Gene Ther 21, 5559 (2010). 13. Evers, M. et al. Targeted disruption in the arylsulfatase B gene results in mice resembling the phenotype of mucopolysaccharidosis VI. Proc Natl Acad Sci U S A 93, 8214 (1996). 14. Ponder, K. P. et al. Neonatal gene therapy with a gamma retroviral vector in mucopolysaccharidosis VI cats.Mupirocin Mol Ther 20, 89807 (2012).6α-Methylprednisolone 21-hemisuccinate sodium salt 15.PMID:23795974 Strauch, O. F. et al. Cardiac and ocular pathologies in a mouse model of mucopolysaccharidosis sort VI. Pediatr Res 54, 701 (2003). 16. Yoshida, M., Ikadai, H., Maekawa, A., Takahashi, M. Nagase, S. Pathological traits of mucopolysaccharidosis VI inside the rat. J Comp Pathol 109, 1413 (1993). 17. Yoshida, M., Noguchi, J., Ikadai, H., Takahashi, M. Nagase, S. Arylsulfatase Bdeficient mucopolysaccharidosis in rats. J Clin Invest 91, 109904 (1993). 18. Sleeper, M. M. et al. Clinical characterization of cardiovascular abnormalities connected with feline mucopolysaccharidosis I and VI. J Inherit Metab Dis 31, 4241 (2008). 19. Baldo, G. et al. Evidence of a progressive motor dysfunction in Mucopolysaccharidosis sort I mice. Behav Brain Res 233, 1695 (2012). 20. Chang, P. L., Lambert, D. T. Pisa, M. A. Behavioral abnormalities inside a murine model of a human lysosomal storage disease. Neuroreport four, 5070 (1993). 21. Hemsley, K. M. Hopwood, J. J. Development of motor deficits in a murine model of mucopolysaccharidosis form IIIA (MPS-IIIA). Behav Brain Res 158, 191 (2005). 22. Langford-Smith, A. et al. Female mucopolysaccharidosis IIIA mice exhibit hyperactivity and a lowered sense of danger in the open field test. PLoS 1 six, e25717 (2011). 23. Langford-Smith, A. et al. Hyperactive behavior in the mouse model of mucopolysaccharidosis IIIB within the open field and residence cage environments. Genes Brain Behav 10, 6732 (2011). 24. Pan, D., Sciascia, A., 2nd, Vorhees, C. V. Williams, M. T. Progression of numerous behavioral deficits with several ages of onset inside a murine model of Hurler syndrome. Brain Res 1188, 2413 (2008). 25. Reolon, G. K. et al. Long-term memory for aversive coaching is impaired in Idua(2/2) mice, a genetic model of mucopolysaccharidosis kind I. Brain Res 1076, 2250 (2006). 26. Crawley, A. C. et al. Characteriza.
